ST2 and Adrenomedullin in Heart Failure

Heart Failure Clinics

Volumn 5, Issue 4, 2009, Pages 515-527

  Kakkar, Rahul ^a   Lee, Richard T ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Adrenomedullin; Biomarker; Heart failure; ST2; Systolic dysfunction

Indexed keywords

ADRENOMEDULLIN; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BIOLOGICAL MARKER; INTERLEUKIN 33; PROTEIN ST2; RECEPTOR PROTEIN; UNCLASSIFIED DRUG;

ACUTE CORONARY SYNDROME; ACUTE HEART FAILURE; ACUTE HEART INFARCTION; CONGESTIVE HEART FAILURE; DISEASE SEVERITY; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HIGH RISK PATIENT; HUMAN; MORTALITY; NONHUMAN; PATHOPHYSIOLOGY; PROGNOSIS; REVIEW; SYMPTOMATOLOGY;

ADRENOMEDULLIN; BIOLOGICAL MARKERS; HEART FAILURE; HUMANS; RECEPTORS, CELL SURFACE; RECEPTORS, INTERLEUKIN-1;

EID: 67650638273     PISSN: 15517136     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hfc.2009.04.009     Document Type: Review

References (75)

1. Braunwald E. Biomarkers in heart failure. N Engl J Med 358 20 (2008) 2148-2159
2. Morrow D.A., and de Lemos J.A. Benchmarks for the assessment of novel cardiovascular biomarkers. Circulation 115 8 (2007) 949-952
3. Tominaga S. A putative protein of a growth specific cDNA from BALB/c-3T3 cells is highly similar to the extracellular portion of mouse interleukin 1 receptor. FEBS Lett 258 2 (1989) 301-304
4. Werenskiold A.K., Hoffmann S., and Klemenz R. Induction of a mitogen-responsive gene after expression of the Ha-ras oncogene in NIH 3T3 fibroblasts. Mol Cell Biol 9 11 (1989) 5207-5214
5. Klemenz R., Hoffmann S., and Werenskiold A.K. Serum- and oncoprotein-mediated induction of a gene with sequence similarity to the gene encoding carcinoembryonic antigen. Proc Natl Acad Sci U S A 86 15 (1989) 5708-5712
6. Werenskiold A.K. Characterization of a secreted glycoprotein of the immunoglobulin superfamily inducible by mitogen and oncogene. Eur J Biochem 204 3 (1992) 1041-1047
7. Takagi T., Yanagisawa K., Tsukamoto T., et al. Identification of the product of the murine ST2 gene. Biochim Biophys Acta 1178 2 (1993) 194-200
8. Yanagisawa K., Takagi T., Tsukamoto T., et al. Presence of a novel primary response gene ST2L, encoding a product highly similar to the interleukin 1 receptor type 1. FEBS Lett 318 1 (1993) 83-87
9. Gachter T., Werenskiold A.K., and Klemenz R. Transcription of the interleukin-1 receptor-related T1 gene is initiated at different promoters in mast cells and fibroblasts. J Biol Chem 271 1 (1996) 124-129
10. Kakkar R., and Lee R.T. The IL-33/ST2 pathway: therapeutic target and novel biomarker. Nat Rev Drug Discov 7 10 (2008) 827-840
11. Lohning M., Stroehmann A., Coyle A.J., et al. T1/ST2 is preferentially expressed on murine Th2 cells, independent of interleukin 4, interleukin 5, and interleukin 10, and important for Th2 effector function. Proc Natl Acad Sci U S A 95 12 (1998) 6930-6935
12. Yanagisawa K., Naito Y., Kuroiwa K., et al. The expression of ST2 gene in helper T cells and the binding of ST2 protein to myeloma-derived RPMI8226 cells. J Biochem 121 1 (1997) 95-103
13. Xu D., Chan W.L., Leung B.P., et al. Selective expression of a stable cell surface molecule on type 2 but not type 1 helper T cells. J Exp Med 187 5 (1998) 787-794
14. Trajkovic V., Sweet M.J., and Xu D. T1/ST2-an IL-1 receptor-like modulator of immune responses. Cytokine Growth Factor Rev 15 2-3 (2004) 87-95
15. Barksby H.E., Lea S.R., Preshaw P.M., et al. The expanding family of interleukin-1 cytokines and their role in destructive inflammatory disorders. Clin Exp Immunol 149 2 (2007) 217-225
16. Bergers G., Reikerstorfer A., Braselmann S., et al. Alternative promoter usage of the Fos-responsive gene Fit-1 generates mRNA isoforms coding for either secreted or membrane-bound proteins related to the IL-1 receptor. Embo J 13 5 (1994) 1176-1188
17. Rossler U., Thomassen E., Hultner L., et al. Secreted and membrane-bound isoforms of T1, an orphan receptor related to IL-1-binding proteins, are differently expressed in vivo. Dev Biol 168 1 (1995) 86-97
18. Oshikawa K., Kuroiwa K., Tago K., et al. Elevated soluble ST2 protein levels in sera of patients with asthma with an acute exacerbation. Am J Respir Crit Care Med 164 2 (2001) 277-281
19. Schmitz J., Owyang A., Oldham E., et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 23 5 (2005) 479-490
20. Weinberg E.O., Shimpo M., De Keulenaer G.W., et al. Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction. Circulation 106 23 (2002) 2961-2966
21. Hill J.A., and Olson E.N. Cardiac plasticity. N Engl J Med 358 13 (2008) 1370-1380
22. Berk B.C., Fujiwara K., and Lehoux S. ECM remodeling in hypertensive heart disease. J Clin Invest 117 3 (2007) 568-575
23. Sanada S., Hakuno D., Higgins L.J., et al. IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J Clin Invest 117 6 (2007) 1538-1549
24. Deswal A., Petersen N.J., Feldman A.M., et al. Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone trial (VEST). Circulation 103 16 (2001) 2055-2059
25. Torre-Amione G. Immune activation in chronic heart failure. Am J Cardiol 95 11 (2005) 3C-8C [discussion: 38C-40C]
26. Fukunaga T., Soejima H., Irie A., et al. Relation between CD4+ T-cell activation and severity of chronic heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 100 3 (2007) 483-488
27. Bartunek J., Delrue L., Van Durme F., et al. Nonmyocardial production of ST2 protein in human hypertrophy and failure is related to diastolic load. J Am Coll Cardiol 52 25 (2008) 2166-2174
28. Shimpo M., Morrow D.A., Weinberg E.O., et al. Serum levels of the interleukin-1 receptor family member ST2 predict mortality and clinical outcome in acute myocardial infarction. Circulation 109 18 (2004) 2186-2190
29. Weinberg E.O., Shimpo M., Hurwitz S., et al. Identification of serum soluble ST2 receptor as a novel heart failure biomarker. Circulation 107 5 (2003) 721-726
30. Januzzi Jr. J.L., Camargo C.A., Anwaruddin S., et al. The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. Am J Cardiol 95 8 (2005) 948-954
31. Januzzi Jr. J.L., Peacock W.F., Maisel A.S., et al. Measurement of the interleukin family member ST2 in patients with acute dyspnea: results from the PRIDE (Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department) study. J Am Coll Cardiol 50 7 (2007) 607-613
32. Rehman S.U., Mueller T., and Januzzi Jr. J.L. Characteristics of the novel interleukin family biomarker ST2 in patients with acute heart failure. J Am Coll Cardiol 52 18 (2008) 1458-1465
33. Sabatine M.S., Morrow D.A., Higgins L.J., et al. Complementary roles for biomarkers of biomechanical strain ST2 and N-terminal prohormone B-type natriuretic peptide in patients with ST-elevation myocardial infarction. Circulation 117 15 (2008) 1936-1944
34. Kitamura K., Kangawa K., Kawamoto M., et al. Adrenomedullin: a novel hypotensive peptide isolated from human pheochromocytoma. Biochem Biophys Res Commun 192 2 (1993) 553-560
35. Kitamura K., Kangawa K., and Eto T. Adrenomedullin and PAMP: discovery, structures, and cardiovascular functions. Microsc Res Tech 57 1 (2002) 3-13
36. Gumusel B., Chang J.K., Hyman A., et al. Adrenotensin: an ADM gene product with the opposite effects of ADM. Life Sci 57 8 (1995) PL87-PL90
37. McLatchie L.M., Fraser N.J., Main M.J., et al. RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor. Nature 393 6683 (1998) 333-339
38. Kuwasako K., Shimekake Y., Masuda M., et al. Visualization of the calcitonin receptor-like receptor and its receptor activity-modifying proteins during internalization and recycling. J Biol Chem 275 38 (2000) 29602-29609
39. Shimekake Y., Nagata K., Ohta S., et al. Adrenomedullin stimulates two signal transduction pathways, cAMP accumulation and Ca2+ mobilization, in bovine aortic endothelial cells. J Biol Chem 270 9 (1995) 4412-4417
40. Ishimitsu T., Nishikimi T., Saito Y., et al. Plasma levels of adrenomedullin, a newly identified hypotensive peptide, in patients with hypertension and renal failure. J Clin Invest 94 5 (1994) 2158-2161
41. Kohno M., Hanehira T., Kano H., et al. Plasma adrenomedullin concentrations in essential hypertension. Hypertension 27 1 (1996) 102-107
42. Lainchbury J.G., Cooper G.J., Coy D.H., et al. Adrenomedullin: a hypotensive hormone in man. Clin Sci (Lond) 92 5 (1997) 467-472
43. Lainchbury J.G., Troughton R.W., Lewis L.K., et al. Hemodynamic, hormonal, and renal effects of short-term adrenomedullin infusion in healthy volunteers. J Clin Endocrinol Metab 85 3 (2000) 1016-1020
44. Meeran K., O'Shea D., Upton P.D., et al. Circulating adrenomedullin does not regulate systemic blood pressure but increases plasma prolactin after intravenous infusion in humans: a pharmacokinetic study. J Clin Endocrinol Metab 82 1 (1997) 95-100
45. Nagaya N., Satoh T., Nishikimi T., et al. Hemodynamic, renal, and hormonal effects of adrenomedullin infusion in patients with congestive heart failure. Circulation 101 5 (2000) 498-503
46. Troughton R.W., Lewis L.K., Yandle T.G., et al. Hemodynamic, hormone, and urinary effects of adrenomedullin infusion in essential hypertension. Hypertension 36 4 (2000) 588-593
47. Nakamura M., Yoshida H., Makita S., et al. Potent and long-lasting vasodilatory effects of adrenomedullin in humans. Comparisons between normal subjects and patients with chronic heart failure. Circulation 95 5 (1997) 1214-1221
48. Nicholls M.G. Hemodynamic and hormonal actions of adrenomedullin. Braz J Med Biol Res 37 8 (2004) 1247-1253
49. Stangl V., Dschietzig T., Bramlage P., et al. Adrenomedullin and myocardial contractility in the rat. Eur J Pharmacol 408 1 (2000) 83-89
50. Szokodi I., Kinnunen P., Tavi P., et al. Evidence for cAMP-independent mechanisms mediating the effects of adrenomedullin, a new inotropic peptide. Circulation 97 11 (1998) 1062-1070
51. Charles C.J., Nicholls M.G., Rademaker M.T., et al. Comparative actions of adrenomedullin and nitroprusside: interactions with ANG II and norepinephrine. Am J Physiol Regul Integr Comp Physiol 281 6 (2001) R1887-R1894
52. Troughton R.W., Frampton C.M., Lewis L.K., et al. Differing thresholds for modulatory effects of adrenomedullin infusion on haemodynamic and hormone responses to angiotensin II and adrenocorticotrophic hormone in healthy volunteers. Clin Sci (Lond) 101 1 (2001) 103-109
53. Hirata Y., Hayakawa H., Suzuki Y., et al. Mechanisms of adrenomedullin-induced vasodilation in the rat kidney. Hypertension 25 4 Pt 2 (1995) 790-795
54. Miura K., Ebara T., Okumura M., et al. Attenuation of adrenomedullin-induced renal vasodilatation by NG-nitro L-arginine but not glibenclamide. Br J Pharmacol 115 6 (1995) 917-924
55. Sugo S., Minamino N., Kangawa K., et al. Endothelial cells actively synthesize and secrete adrenomedullin. Biochem Biophys Res Commun 201 3 (1994) 1160-1166
56. Sugo S., Minamino N., Shoji H., et al. Production and secretion of adrenomedullin from vascular smooth muscle cells: augmented production by tumor necrosis factor-alpha. Biochem Biophys Res Commun 203 1 (1994) 719-726
57. Jougasaki M., Wei C.M., McKinley L.J., et al. Elevation of circulating and ventricular adrenomedullin in human congestive heart failure. Circulation 92 3 (1995) 286-289
58. Perez-Villa F., Leivas A., Roig E., et al. Adrenomedullin messenger RNA expression is increased in myocardial tissue of patients with idiopathic dilated cardiomyopathy. J Heart Lung Transplant 23 11 (2004) 1297-1300
59. Jougasaki M., Rodeheffer R.J., Redfield M.M., et al. Cardiac secretion of adrenomedullin in human heart failure. J Clin Invest 97 10 (1996) 2370-2376
60. Tsuruda T., Kato J., Kitamura K., et al. Adrenomedullin: a possible autocrine or paracrine inhibitor of hypertrophy of cardiomyocytes. Hypertension 31 1 Pt 2 (1998) 505-510
61. Autelitano D.J., Ridings R., and Tang F. Adrenomedullin is a regulated modulator of neonatal cardiomyocyte hypertrophy in vitro. Cardiovasc Res 51 2 (2001) 255-264
62. Kato J., Tsuruda T., Kitamura K., et al. Adrenomedullin: a possible autocrine or paracrine hormone in the cardiac ventricles. Hypertens Res 26 Suppl (2003) S113-S119
63. Swaney J.S., Roth D.M., Olson E.R., et al. Inhibition of cardiac myofibroblast formation and collagen synthesis by activation and overexpression of adenylyl cyclase. Proc Natl Acad Sci U S A 102 2 (2005) 437-442
64. Nishikimi T., Yoshihara F., Mori Y., et al. Cardioprotective effect of adrenomedullin in heart failure. Hypertens Res 26 Suppl (2003) S121-S127
65. Kato K., Yin H., Agata J., et al. Adrenomedullin gene delivery attenuates myocardial infarction and apoptosis after ischemia and reperfusion. Am J Physiol Heart Circ Physiol 285 4 (2003) H1506-H1514
66. Nakamura R., Kata J., Kitamura K., et al. Beneficial effects of adrenomedullin on left ventricular remodeling after myocardial infarction in rats. Cardiovasc Res 56 3 (2002) 373-380
67. Nakamura R., Kata J., Kitamura K., et al. Adrenomedullin administration immediately after myocardial infarction ameliorates progression of heart failure in rats. Circulation 110 4 (2004) 426-431
68. Nishikimi T., Saito Y., Kitamura K., et al. Increased plasma levels of adrenomedullin in patients with heart failure. J Am Coll Cardiol 26 6 (1995) 1424-1431
69. Kobayashi K., Kitamura K., Hirayama N., et al. Increased plasma adrenomedullin in acute myocardial infarction. Am Heart J 131 4 (1996) 676-680
70. Morales M.A., Del Ry S., Startari U., et al. Plasma adrenomedullin relation with Doppler-derived dP/dt in patients with congestive heart failure. Clin Cardiol 29 3 (2006) 126-130
71. Yu C.M., Cheung B.M., Leung R., et al. Increase in plasma adrenomedullin in patients with heart failure characterised by diastolic dysfunction. Heart 86 2 (2001) 155-160
72. Richards A.M., Nicholls M.G., Yandle T.G., et al. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: new neurohormonal predictors of left ventricular function and prognosis after myocardial infarction. Circulation 97 19 (1998) 1921-1929
73. Richards A.M., Doughty R., Nicholls M.G., et al. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group. J Am Coll Cardiol 37 7 (2001) 1781-1787
74. Khan S.Q., O'Brien R.J., Struck J., et al. Prognostic value of midregional pro-adrenomedullin in patients with acute myocardial infarction: the LAMP (Leicester Acute Myocardial Infarction Peptide) study. J Am Coll Cardiol 49 14 (2007) 1525-1532
75. Gegenhuber A., Struck J., Dieplinger B., et al. Comparative evaluation of B-type natriuretic peptide, mid-regional pro-A-type natriuretic peptide, mid-regional pro-adrenomedullin, and Cope tin to predict 1-year mortality in patients with acute destabilized heart failure. J Card Fail 13 1 (2007) 42-49